title: Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and.
abstract: Radiolabelled ganciclovir analogues have shown promise as imaging agents to detect herpes simplex virus thymidine kinase (HSVtk) expression. This study evaluated the use of positron emission tomography (PET) imaging with 9-[(3-[18F]fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]FHPG) to assess gene transfer into tumours. HSVtk-positive and HSVtk-negative cell lines were first treated in vitro with [18F]FHPG. To assess the efficacy of PET in detecting HSVtk expression following in vivo gene transfer, mice were injected intravenously with an adenovirus encoding HSVtk (Ad.HSVtk), a control vector (Ad.Bgl2) or saline. Subcutaneous human glioma xenografts were grown in mice and treated by direct injection of Ad.HSVtk or Ad.Bgl2. Imaging was performed 48 h after transduction. Similar experiments were performed using Fischer rats implanted with syngeneic tumours. The presence of the HSVtk protein was confirmed by immunohistochemistry. Biodistribution studies were also obtained in 14 naive mice. In vitro studies showed high and specific uptake of [18F]FHPG in HSVtk-positive cell lines, with an uptake ratio of up to 27:1. PET imaging and direct counting of major organs demonstrated HSVtk-specific tracer retention. In mice, HSVtk-positive tumours retained 3.4% dose/gram as compared to 0.6% for control tumours (P=0.03). They were clearly seen on the PET images as early as 100 min post injection. Similar results were obtained with syngeneic rat tumours. Biodistribution studies demonstrated the rapid distribution and clearance of the tracer in all major organs. Our results demonstrate that PET imaging of HSVtk gene transfer to tumours is feasible and is highly specific for HSVtk expression.
authors.affiliation: Department of Radiology, University of Pennsylvania, Philadelphia, USA. rhustinx@chu.ulg.ac.be
authors.forename: R
authors.initials: R
authors.lastname: Hustinx
authors.forename: C Y
authors.initials: CY
authors.lastname: Shiue
authors.forename: A
authors.initials: A
authors.lastname: Alavi
authors.forename: D
authors.initials: D
authors.lastname: McDonald
authors.forename: G G
authors.initials: GG
authors.lastname: Shiue
authors.forename: H
authors.initials: H
authors.lastname: Zhuang
authors.forename: M
authors.initials: M
authors.lastname: Lanuti
authors.forename: E
authors.initials: E
authors.lastname: Lambright
authors.forename: J S
authors.initials: JS
authors.lastname: Karp
authors.forename: S L
authors.initials: SL
authors.lastname: Eck
mesh_terms: D000818:Animals; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008654:Mesothelioma / Q000000981:diagnostic imaging / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D011916:Rats, Inbred F344; D018139:Simplexvirus / Q000201:enzymology* / Q000235:genetics*; D013937:Thymidine Kinase / Q000235:genetics*; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
chemical_list: C104325:9-((3-fluoro-1-hydroxy-2-propoxy)methyl)guanine; D019275:Radiopharmaceuticals; D013937:Thymidine Kinase; D015774:Ganciclovir